Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Epidemiological characteristics of gastric and pancreatic cancers in Latin America: The LACOG 0222 GASPAR study.
Authors
Renata D'Alpino Peixoto
Grupo Oncoclínicas, São Paulo, Brazil
Renata D'Alpino Peixoto , Diogo Bugano Diniz Gomes , Victor Hugo Fonseca Jesus , Rui Fernando Weschenfelder , Antonio Soares Dias Jr , Anelisa Kruschewsky Coutinho Araujo , Rafaela Gomes de Jesus , Matheus Soares Rocha , Gustavo Cartaxo de Lima Gössling
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr TPS710)
DOI
10.1200/JCO.2024.42.3_suppl.TPS710
Abstract #
TPS710
Poster Bd #
P19
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A pilot study of liposomal irinotecan plus 5-FU/ LV combined with paricalcitol in patients with advanced pancreatic cancer which progressed on gemcitabine-based therapy.
First Author: Patrick Grierson
Poster
2019 Gastrointestinal Cancers Symposium
Dose intensity of nab-paclitaxel and gemcitabine chemotherapy in metastatic pancreatic cancer.
First Author: Alexander Lim
Poster
2017 ASCO Quality Care Symposium
Uptake and effectiveness of FOLFIRINOX for advanced pancreas cancer: A population-based study.
First Author: Safiya Karim
Poster
2016 Gastrointestinal Cancers Symposium
Early tumor shrinkage as a predictor of favorable outcomes in patients (pts) with advanced pancreatic cancer treated with FOLFIRINOX.
First Author: Yasuhiro Kaga